Chinyere E Okpara
Overview
Explore the profile of Chinyere E Okpara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
200
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grunwald V, McKay R, Buchler T, Eto M, Park S, Takagi T, et al.
Int J Cancer
. 2024 Dec;
156(7):1326-1335.
PMID: 39739622
Lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib in treatment of advanced renal cell carcinoma (aRCC) in the phase 3 CLEAR study. We report results of an exploratory post hoc...
2.
Marth C, Moore R, Bidzinski M, Pignata S, Ayhan A, Rubio M, et al.
J Clin Oncol
. 2024 Nov;
43(9):1083-1100.
PMID: 39591551
Purpose: Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) in the phase...
3.
ODonnell P, Loriot Y, Csoszi T, Matsubara N, Shin S, Park S, et al.
Cancer
. 2024 Oct;
131(1):e35601.
PMID: 39465550
Background: First-line pembrolizumab monotherapy is a standard of care for platinum-ineligible patients with advanced urothelial carcinoma (UC). No global standardized definition of platinum ineligibility exists. This study aimed to evaluate...
4.
Gaspar N, Hung G, Strauss S, Campbell-Hewson Q, Dela Cruz F, Glade Bender J, et al.
JAMA Oncol
. 2024 Oct;
10(12):1645-1653.
PMID: 39418029
Importance: The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines. Objective: To evaluate whether the addition...
5.
Chung H, Saada-Bouzid E, Longo F, Yanez E, Im S, Castanon E, et al.
Cancer
. 2024 Jul;
130(19):3278-3288.
PMID: 39031824
Background: Novel treatments are needed for patients with advanced, triple-negative breast cancer (TNBC) that progresses or recurs after first-line treatment with chemotherapy. The authors report results from the TNBC cohort...
6.
Lee C, Shah A, Rao A, Taylor M, Di Simone C, Hsieh J, et al.
Eur Urol
. 2024 May;
86(5):470-473.
PMID: 38777648
No abstract available.
7.
Gonzalez-Martin A, Chung H, Saada-Bouzid E, Yanez E, Senellart H, Cassier P, et al.
Gynecol Oncol
. 2024 May;
186:182-190.
PMID: 38718741
Objectives: The phase 2, multicohort, open-label LEAP-005 study evaluated lenvatinib plus pembrolizumab in patients with previously treated advanced solid tumors. We report outcomes from the ovarian cancer cohort. Methods: Eligible...
8.
Grunwald V, Powles T, Eto M, Kopyltsov E, Rha S, Porta C, et al.
Front Oncol
. 2024 Mar;
13:1343027.
PMID: 38495081
[This corrects the article DOI: 10.3389/fonc.2023.1223282.].
9.
Motzer R, Porta C, Eto M, Powles T, Grunwald V, Hutson T, et al.
J Clin Oncol
. 2024 Jan;
42(11):1222-1228.
PMID: 38227898
JCO We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up...
10.
Yang J, Han B, de la Mora Jimenez E, Lee J, Koralewski P, Karadurmus N, et al.
J Thorac Oncol
. 2023 Dec;
19(6):941-953.
PMID: 38159809
Introduction: Lenvatinib plus pembrolizumab was found to have antitumor activity and acceptable safety in previously treated metastatic NSCLC. We evaluated first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in metastatic...